Table 3 Summary of adverse events (AEs) by treatment group
Event | NeuroEPO plus 0.5 mg (n = 57) | NeuroEPO plus 1.0 mg (n = 56) | Placebo (n = 57) |
|---|---|---|---|
Overview of AE — no. (%) | |||
Participants with any AE | 5 (8.8) | 3 (5.4) | 3 (5.3) |
AE related to neuroEPO plus or placebo | 1 (1.8) | 0 | 0 |
Serious AE | 3 (5.3) | 0 | 3 (5.3) |
Death (not related to treatment) | 1 (1.8) | 0 | 1(1.8) |
Participants with ≥ 1 serious AE | 1 (1.8) | 0 | 1(1.8) |
AE that occurred in either group | |||
Bronchopneumonia | 1(1.8) | 0 | 1(1.8) |
Pulmonary embolism | 1 (1.8) | 0 | 0 |
Numbness upper right member | 1 (1.8) | 0 | 0 |
Bronchopneumonia | 1 (1.8) | 0 | 0 |
Fall down | 0 | 0 | 1(1.8) |
Headache | 1 (1.8) | 0 | 0 |
Nasal congestion | 1 (1.8) | 0 | 0 |
Constipation | 1 (1.8) | 0 | 0 |
Dehydration | 0 | 0 | 1(1.8) |
Pain due to fall down | 0 | 0 | 1(1.8) |
Flu status | 0 | 1 (1.8) | 0 |
Hypertension | 0 | 1 (1.8) | 0 |
Hematoma due to fall down | 0 | 0 | 1 (1.8) |
Urinary sepsis | 0 | 1 (1.8) | 0 |
Irritability | 0 | 0 | 1 (1.8) |
Palpitations | 1 (1.8) | 0 | 0 |
Deep venous thrombosis | 1 (1.8) | 0 | 0 |
Vomiting | 1 (1.8) | 1 (1.8) | 1 (1.8) |
Diarrhea | 0 | 1 (1.8) | 0 |